Replay available

Apotea (Stockholm:APOTEA) Q2 2026 Earnings Call

Apotea (Stockholm:APOTEA) Q2 2026 earnings call, held 2026-07-17. Watch the replay and read the transcript on 6ix.

Fri, July 17, 2026 at 3:30 AMendedReplay
Apotea (Stockholm:APOTEA) Q2 2026 Earnings Call
Company
Apotea AB (OMXSTO:APOTEA)
Period
Q2 2026 earnings call
Date
Fri, Jul 17, 2026, 3:30 AM ET
Replay
Watch the replay on this page · 23 min

On 6ix: 6ix.com/event/apotea-ab-apotea-q2-2026-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good morning everyone and welcome to the presentation of Apothea's second quarter report. As usual we will start with a presentation and after the presentation is done we will move on to a Q&A with spoken questions. Today's presenters are Per Svärdson, CEO and co-founder, Johan Morill, CFO and myself, Sara Ahlström, COO. And we will begin with some highlights of the quarterly figures.

0:33 Yeah, hello. I think we have had a good quarter with good profitability and stable growth. So Johan, please show us the figures.

0:45 Yes, we had revenues of 2 billion and 26 million in the quarter and a growth of 10 points. 9%. We had a strong profitability in the quarter. We increased adjusted EBIT and had an adjusted EBIT margin of 5.2%.

1:07 Yeah, and if we look at the second quarter, I think we have had a good progress on our growth initiatives. I mean, it consists of a lot of small projects from everything from like assortment stock levels the customer journey and so on but I think we have a good speed it takes some time but we will absolutely see effect on that in the coming year so please Sarah show us a little bit more about them

1:43 Perfect, exactly. Some examples of these sales initiatives. One is of course the launch of apotea.no. At the end of May we did the soft launch of the site and we are now selling our beauty and health assortment into the Norwegian market. and during this quarter we have also began with some marketing activities still in a small scale and started to scale up the sales. We have went from a few orders each day to a couple of hundreds and the ambition is of course to continue to strengthening our position in the Norwegian market. We have also continued to scale up the production in our new fulfillment center in Barberg We are working quite a lot with optimizing the operation, so we will continue to do so.

2:31 We are quite pleased to see that the higher share of the larger orders are now being handled by this automated facility, which we are very pleased about. And we also had a new high score during the quarter, and we are now producing more than 30,000 orders in a day. At the end of May we also rolled out a company-wide share program of dShares, enabling our colleagues from the office prescription hubs and also the fulfillment center to participate, which we are very happy about.

3:04 We had with the revenue in the quarter approaching now rolling fund months revenue of 7.6 billion and an adjusted EBIT margin for the same period of 4.2%, which was in line with the rolling fund months number in Q1. Let's take a look on the numbers in more details. We had revenues exceeding 2 billion in the quarter, and as mentioned, a stable growth. of 10.9%. We had a slightly higher growth rate in RX, but we had stable growth in both OTC and Traders Goods, as well as in RX. RX continued to increase its share of the revenues in the quarter.

3:52 To the right, you can see our gross margin development, and we had a stable gross margin in the quarter. We had a strong profitability in the quarter. We increased adjusted EBIT to 105 million SEK despite increased depreciation of more than 17 million krona. And we had an adjusted EBIT margin of 5.2%. if you look to the right you can see a selected our operating costing percentage of revenue and as expected the depreciations and amortizations increased and that is result of the I shouldn't say new fulfillment center in Varbergh but the fulfillment center in Varbergh established last year and at the same time we had an improved efficiency as as you can see in decline of personnel and other external expenses in percentage of revenues and improved efficiency is the result of continuing good cost control but also we get better cost leverage as we increase the capacity utilization If you look on year to date,

5:23 we for the first half year had a stable growth of 10.7% and also looking at the first half year, RH grew slightly higher than OTC and traded goods and increased its share of revenues. Adjusted EBIT increased to 206 million and that corresponds to an adjusted EBIT margin of 5.2% and also for the first half year where there was a high increase as expected in depreciation. Depreciation and amortizations for the first half year increased roughly 35 million. We had lower operating cash flow in Q2 as well as in year to date.

6:16 The operating cash flow was impacted by inventory and the inventory has increased in part due to inventory build up in Varberg, but also temporary measures to ensure a robustness in the supply chain as we've highlighted before. To the right you can see our capex. We have following the completion of the fulfillment center in Varberg had a significantly lower investment pace and half year we have very limited investments. And as we now are scaling up the production in Varberg and at the same time also evaluating and figuring out what new investments that are best suited for these operations.

7:12 Investments are likely to remain low this year. However, if you look on the longer period between investments related to new fulfillment centers, we are still expecting a yearly average of capex of 50 to 70 million krona. We had an inventory of slightly above 850 million at the end of June. Over the course of the last year, we have increased inventory, mainly due to the buildup of inventory in Varberg. And as a consequence of the increased inventory, inventory turnover have also decreased. We expect to gradually increase the inventory turnover as capacity utilization increases but also by further optimization.

8:17 Let's take a look on the return on capital employed. We have a high return on capital employed of 27 million, although it has declined over the past year. as a result of the fulfillment center in Varberg. And to the right, you can see our net debt and net cash position. And at the end of June, we had continued to have a very strong balance sheet and a cash position of 104 million SEK. And this is despite an increased inventory and also dividend paid out in Q2 of roughly 62 million SEK.

9:08 Yeah, and if we look on our focus ahead, we will continue to focus on growth initiatives, but also to build the pharmacy of tomorrow. And when we say building the pharmacy of tomorrow, it means that have a continuous journey to improve everything to make it better for the customer. So a lot of these small everyday steps and you can never succeed with them. It's forever travel and I think to have a goal that says that you want to change all the time is very important in our business and we will continue to focus on that and Sara will give us some examples.

9:59 Exactly, growth remains our main focus also going forward. I think we have to look through all parts of the customer journey to make sure that we are excellent in every step and that includes, as Per mentioned in the beginning, it includes the assortment, the pricing, features on the site, the information regarding the deliveries and so on. We have to be excellent in all aspects and improve even further. We will of course also focus on apotea.no as I said in the beginning we have just started with the marketing activities so we will start to continue to increase the marketing activities and step by step also increase the sales. and we want to make sure that we still have or that we continue to develop the customer offering also in Norway to make sure that that's a good offering also on the Norwegian market.

10:49 We also want to continue to focus and continue to improve the RX offering and the offering of prescribed medicine We want to make it even easier for the customers to order online. We have before said examples such as expanding the assortment of prescribed medicine that demand cold spread, also expanding the deliveries of cold spread. We also mentioned digital inhalation guidance as a pharmaceutical service and those types of initiatives we will continue to launch to make sure that we are a pharmacy of tomorrow also going forward. That was the end of the presentation, so we will move on to a Q&A with spoken questions. The next question comes from Benjamin Wahlstedt from ABGSC.

11:40 Please go ahead.

11:44 Hello, I was wondering firstly if you could elaborate on the organic growth trajectory a bit. You've previously commented that you expect a gradually higher growth rate throughout the year, but also that it takes some time. So I was wondering just how should we weigh these statements against each other, please?

12:05 I can start a little bit discussing it. I mean a lot of these initiatives are like small steps and you first you need to build it or first you design it and you build it and then the customer realize that it's easier and then so it takes some time and I think we can increase the growth with like single digits of percentage every quarter or something like that, but it takes time. But over like one year or something, I think you can see a big difference, but it takes some time.

12:50 I think it takes too much time sometimes, but it does. Do you have any more comments on that, Sara and Johan?

13:00 No, I think, and as mentioned, growth initiative is our main focus and we're not satisfied with the growth rate.

13:13 Thank you very much. Second of all, you comment on a gradual ramping up in marketing spend related to Norway. and I was just wondering what sort of magnitudes are you talking about here? Is this something that you expect to move company profits?

13:33 I think you see it.

13:35 Yes, sorry.

13:36 Just a short, we are still in the very beginning of it and I think the marketing activities are so far in a small scale and we will ramp it up very gradually and step by step to just make that clear.

13:50 And compared to Sweden, it's almost zero. So, I mean, if you take it from a result perspective, it's nothing. But for Norway, it's a big step. Yeah, perfect.

14:08 and then I was wondering about the incentive program structure and I understand this is not something you decide all by yourself it's a shareholder decision but then again you also own quite a large part of total shares both directly and indirectly you start receiving EVIT related shares already at a three percent margin all the way until 2028 and I was just I mean, a 3% margin in 2028 looks like a fairly guaranteed payday. On the other hand, your growth targets look more forward-leaning. Growth incentive shares start kicking in at growth of 15%. So should we sort of expect you to dig a bit deeper into the margins to ramp up growth in your term? Is that how we should interpret the the incentive program or what are we missing?

15:03 We tried to correlate the incentive program with the financial targets because I think it's important to have financial or incentive programs that correlates to what we tell the market because we want them to be correlated. Otherwise, it sounds very strange. So that's what we have tried to do. And I mean, this de-share program that we also launched was just normal shares but with some kind of technical construction so it's easier to buy them. But I think it's important that our employees have shares as well and share the same goal that the market does because then we can have the same targets.

15:59 Do you want to add something to that?

16:02 No, just as mentioned the D shares following the kind of is a hurdle share construction and following this more or less the same structure that we had before with the C shares and they were also offered and company wide as we've done in the past.

16:25 All right, so we should not take the levels of the targets as suggesting a change in strategy from here on out?

16:34 No.

16:35 No, they just follow the financial targets. All right, perfect. That's all I have for now. Thank you very much.

16:42 Thank you. Thanks. The next question comes from Amina Ashraf from Dansky Bank. Please go ahead.

16:52 Good morning, and thank you for taking my question. And I'm actually very interested to hear more about your beauty and health assortment. You mentioned that there is significant upside potential in the expansion in Norway. So maybe you can shed a bit light on how different the consumer behavior is within the beauty consumption in Norway versus Sweden.

17:16 I think it's actually too early stage to kind of discuss the differences too much. I think we're too early on to make any assumptions based on the consumer so far. But what we can say is that we see great potential in Norway and we also see great potential both in the pharmacy market where we present through apotea.no and also through the beauty and health assortment through apotea.no. So I think it's great potential in the Norwegian market, and we're still quite small, and we expect to have a growth path in the Norwegian market.

17:51 That's quite fair.

17:52 It's only been...

17:55 Sorry, go ahead. Just to add to that, I mean, we have a pharmacy offering in Norway, and with the soft launch of apotea.no in the end of April, we're also complementing that with the beauty and health assortment. that is available to the Swedish customers. And we have a fairly large beauty and health sales and a strong position in those segments in Sweden. And of course, we see a potential to kind of further leverage that strength in the Norwegian market that we regard as attractive.

18:36 No, I completely agree. My market research shows that Norway is a very attractive market as well. But if I ask you then with regards to how much beauty contributes to your total revenue, if I go scrape your website in Sweden, correct me if I'm wrong, but approximately 41% of your online assortment is beauty and health. Are you expecting that to be the same in Norway as well?

19:05 It is a fair share of our total sales, and we see great potential in it, both in the Swedish market and the Norwegian market. And I think we have two different offerings in the Norwegian market currently. One, a very specific pharmacy offering with assortment related to the pharmacy industry, and the other one is a pure beauty and health assortment that we ship currently from our VARBI facility. So it's a related assortment to the Swedish one, if that answers your question.

19:37 All right, and given that information, could you shed any light compared to your total revenues? How much beauty and health makes up of that?

19:46 We haven't disclosed that in specific. We have done it historically a couple of years, I would now say, before. And then we stated there was past one billion, but we haven't shared that number since then.

19:59 But we can say that it's a healthy growth in those segments. And just to be clear, I mean, it's not one segment. It's a lot of different categories that may build up of these And it's a natural part of being a pharmacy and also Apotheas for a long time been a front runner in expanding and strengthening the role of the pharmacy and including health and beauty products in that offering.

20:32 Yeah, absolutely. So that historical number you share, what percentage of the total sales was that?

20:41 I think it's not fair to say, because we can't, I'm not sure exactly when we'll release that figure, but it's a press release that you can find. And we haven't disclosed

20:54 it. Would it be fair to assume that it's in line with the percentage of the assortment? I mean, the 41% that my scraping talents tells me.

21:09 I think it's difficult to look at the number because I mean mascara and a lipstick has a lot of skews so I mean I'll say that it's difficult to say that I don't have the percentage on top of my mind actually but yeah

21:27 And then you said 41% of the total number of SKUs. And then when we said this 1 billion, it was maybe more like half of that in relation. So, I mean, because on the pharmacy side, you have like painkillers, you have this OTC product that sells a lot. So I think you can more like... divided by two. It's a rough, but that's a very rough number, but then you have something.

22:08 All right. Well, thank you so much. That was very exciting to hear about the beauty and health assortment. Thank you.

22:19 And that was also the last question for today. So thank you very much for listening to the presentation despite the very sunny and warm weather in Sweden. And thank you for today.

22:30 Thank you very much. Thank you.

Follow Apotea AB into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Johan Morill

CFO

Amina Ashraf

Analyst at Danske Bank

Sara Ahlström

COO

Benjamin Wahlstedt

Analyst at ABGSC

Per Svärdson

CEO and Co-founder

More from Apotea AB